ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- Phosphorescent Iridium Hydrazinonicotinic Acid (HYNIC) Complexes That Bind to Prostate Specific Membrane Antigen: Potential Photodynamic Therapy of Prostate Cancer.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Article
- Review
- Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics.EJNMMI research · 2025Review
- Review
- Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review.Biomedicines · 2025Review
- Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.Journal of medicinal chemistry · 2025Review
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Tuning the Properties of Rigidified Acyclic DEDPAInorganic chemistry · 2024Article
- Application of Advanced Imaging to Prostate Cancer Diagnosis and Management: A Narrative Review of Current Practice and Unanswered Questions.Journal of clinical medicine · 2024Review
- Cancer theragnostics: closing the loop for advanced personalized cancer treatment through the platform integration of therapeutics and diagnostics.Frontiers in bioengineering and biotechnology · 2024Review
- Multiple angiolipomas visualized by dynamic and delayed "total-body" [European journal of nuclear medicine and molecular imaging · 2023Article
- Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy.Cancers · 2023Review
- Radiochemical and Biological Evaluation of 3p-Pharmaceuticals (Basel, Switzerland) · 2023Article
- Recent Advances inInternational journal of molecular sciences · 2023Review
- Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer.Molecules (Basel, Switzerland) · 2023Article
- Radiotheranostics in oncology: current challenges and emerging opportunities.Nature reviews. Clinical oncology · 2022Review
- Advances in PSMA theranostics.Translational oncology · 2022Article
- Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2022Article
- A feasibility study of the therapeutic application of a mixture ofMedical physics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.